Skip to main content
NCBI home page
Clinical and Diagnostic Laboratory Immunology logoLink to Clinical and Diagnostic Laboratory Immunology
. 1995 Sep;2(5):509–517. doi: 10.1128/cdli.2.5.509-517.1995

Clinical utility of complement assessment.

A E Ahmed 1, J B Peter 1
PMCID: PMC170192  PMID: 8548527

Full Text

The Full Text of this article is available as a PDF (213.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abou-Ragheb H. H., Williams A. J., Brown C. B., Milford-Ward A. Plasma levels and mode of excretion of the anaphylatoxins C3a and C4a in renal disease. J Clin Lab Immunol. 1991 Jul;35(3):113–119. [PubMed] [Google Scholar]
  2. Abou-Ragheb H. H., Williams A. J., Brown C. B., Milford-Ward A. Plasma levels of the anaphylatoxins C3a and C4a in patients with IgA nephropathy/Henoch-Schönlein nephritis. Nephron. 1992;62(1):22–26. doi: 10.1159/000186989. [DOI] [PubMed] [Google Scholar]
  3. Abramson S. B., Buyon J. P. Activation of the complement pathway: comparison of normal pregnancy, preeclampsia, and systemic lupus erythematosus during pregnancy. Am J Reprod Immunol. 1992 Oct-Dec;28(3-4):183–187. doi: 10.1111/j.1600-0897.1992.tb00787.x. [DOI] [PubMed] [Google Scholar]
  4. Abramson S. B., Weissmann G. Complement split products and the pathogenesis of SLE. Hosp Pract (Off Ed) 1988 Dec 15;23(12):45–56. doi: 10.1080/21548331.1988.11703590. [DOI] [PubMed] [Google Scholar]
  5. Adinolfi M. Human complement: onset and site of synthesis during fetal life. Am J Dis Child. 1977 Sep;131(9):1015–1023. doi: 10.1001/archpedi.1977.02120220081015. [DOI] [PubMed] [Google Scholar]
  6. Ahmed A. E., Veitch J., Whaley K. Mechanism of action of an inhibitor of complement-mediated prevention of immune precipitation. Immunology. 1990 Jun;70(2):139–144. [PMC free article] [PubMed] [Google Scholar]
  7. Asghar S. S., Schraag B., Backhaus A. H., Zorn I., Venneker G. T., Hannema A. J. A new method for the estimation of C3d. Affinity clearance of C-determinant-bearing C3 molecules and fragments followed by estimation of C3d by ELISA. J Immunol Methods. 1989 Jun 21;120(2):207–214. doi: 10.1016/0022-1759(89)90244-5. [DOI] [PubMed] [Google Scholar]
  8. Auda G., Holme E. R., Davidson J. E., Zoma A., Veitch J., Whaley K. Measurement of complement activation products in patients with chronic rheumatic diseases. Rheumatol Int. 1990;10(5):185–189. doi: 10.1007/BF02274831. [DOI] [PubMed] [Google Scholar]
  9. Belmont H. M., Hopkins P., Edelson H. S., Kaplan H. B., Ludewig R., Weissmann G., Abramson S. Complement activation during systemic lupus erythematosus. C3a and C5a anaphylatoxins circulate during exacerbations of disease. Arthritis Rheum. 1986 Sep;29(9):1085–1089. doi: 10.1002/art.1780290905. [DOI] [PubMed] [Google Scholar]
  10. Bergamaschini L., Gardinali M., Poli M., Lorini R., Bosi E., Agostoni A. Complement activation in diabetes mellitus. J Clin Lab Immunol. 1991 Jul;35(3):121–127. [PubMed] [Google Scholar]
  11. Burger R., Zilow G., Bader A., Friedlein A., Naser W. The C terminus of the anaphylatoxin C3a generated upon complement activation represents a neoantigenic determinant with diagnostic potential. J Immunol. 1988 Jul 15;141(2):553–558. [PubMed] [Google Scholar]
  12. Butler J., Rocker G. M., Westaby S. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 1993 Feb;55(2):552–559. doi: 10.1016/0003-4975(93)91048-r. [DOI] [PubMed] [Google Scholar]
  13. Buyon J. P., Tamerius J., Belmont H. M., Abramson S. B. Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Comparison of the use of complement split products and conventional measurements of complement. Arthritis Rheum. 1992 Sep;35(9):1028–1037. doi: 10.1002/art.1780350907. [DOI] [PubMed] [Google Scholar]
  14. Cat R., Rosario N. A., de Messias I. T., Resener T. D., Kirschfink M. Evaluation of complement activation in premature newborn infants with hyaline membrane disease. Eur J Pediatr. 1993 Mar;152(3):205–208. doi: 10.1007/BF01956145. [DOI] [PubMed] [Google Scholar]
  15. Charlesworth J. A., Williams D. G., Sherington E., Lachmann P. J., Peters D. K. Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia. J Clin Invest. 1974 Jun;53(6):1578–1587. doi: 10.1172/JCI107708. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Clough J. D., Barna B. P., Danao-Camara T. C., Chang R. K. Serological detection of disease activity in SLE. Clin Biochem. 1992 Jun;25(3):201–208. doi: 10.1016/0009-9120(92)90315-j. [DOI] [PubMed] [Google Scholar]
  17. Colten H. R., Rosen F. S. Complement deficiencies. Annu Rev Immunol. 1992;10:809–834. doi: 10.1146/annurev.iy.10.040192.004113. [DOI] [PubMed] [Google Scholar]
  18. Compston A., Scolding N., Wren D., Noble M. The pathogenesis of demyelinating disease: insights from cell biology. Trends Neurosci. 1991 May;14(5):175–182. doi: 10.1016/0166-2236(91)90099-g. [DOI] [PubMed] [Google Scholar]
  19. Coupes B. M., Kon S. P., Brenchley P. E., Short C. D., Mallick N. P. The temporal relationship between urinary C5b-9 and C3dg and clinical parameters in human membranous nephropathy. Nephrol Dial Transplant. 1993;8(5):397–401. [PubMed] [Google Scholar]
  20. Dalmasso A. P. Complement in the pathophysiology and diagnosis of human diseases. Crit Rev Clin Lab Sci. 1986;24(2):123–183. doi: 10.3109/10408368609110272. [DOI] [PubMed] [Google Scholar]
  21. Dalmasso A. P. The complement system in xenotransplantation. Immunopharmacology. 1992 Sep-Oct;24(2):149–160. doi: 10.1016/0162-3109(92)90020-d. [DOI] [PubMed] [Google Scholar]
  22. Dauchel H., Joly P., Delpech A., Thomine E., Sauger F., Le Loet X., Lauret P., Tron F., Fontaine M., Ripoche J. Local and systemic activation of the whole complement cascade in human leukocytoclastic cutaneous vasculitis; C3d,g and terminal complement complex as sensitive markers. Clin Exp Immunol. 1993 May;92(2):274–283. doi: 10.1111/j.1365-2249.1993.tb03392.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Drew J. H., Arroyave C. M. The complement system of the newborn infant. Biol Neonate. 1980;37(3-4):209–217. doi: 10.1159/000241276. [DOI] [PubMed] [Google Scholar]
  24. Figueredo A., Ibarra J. L., Bagazgoitia J., Rodriguez A., Molino A. M., Fernandez-Cruz A., Patino R. Plasma C3d levels and ischemic heart disease in type II diabetes. Diabetes Care. 1993 Feb;16(2):445–449. doi: 10.2337/diacare.16.2.445. [DOI] [PubMed] [Google Scholar]
  25. Fredrikson G. N., Truedsson L., Sjöholm A. G. New procedure for the detection of complement deficiency by ELISA. Analysis of activation pathways and circumvention of rheumatoid factor influence. J Immunol Methods. 1993 Dec 3;166(2):263–270. doi: 10.1016/0022-1759(93)90367-g. [DOI] [PubMed] [Google Scholar]
  26. Friedl H. P., Till G. O., Trentz O., Ward P. A. Roles of histamine, complement and xanthine oxidase in thermal injury of skin. Am J Pathol. 1989 Jul;135(1):203–217. [PMC free article] [PubMed] [Google Scholar]
  27. Gibran N. S., Heimbach D. M. Mediators in thermal injury. Semin Nephrol. 1993 Jul;13(4):344–358. [PubMed] [Google Scholar]
  28. Gillinov A. M., DeValeria P. A., Winkelstein J. A., Wilson I., Curtis W. E., Shaw D., Yeh C. G., Rudolph A. R., Baumgartner W. A., Herskowitz A. Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass. Ann Thorac Surg. 1993 Mar;55(3):619–624. doi: 10.1016/0003-4975(93)90264-i. [DOI] [PubMed] [Google Scholar]
  29. Gorski J. P. Quantitation of human complement fragment C4ai in physiological fluids by competitive inhibition radioimmune assay. J Immunol Methods. 1981;47(1):61–73. doi: 10.1016/0022-1759(81)90257-x. [DOI] [PubMed] [Google Scholar]
  30. Hack C. E., Nuijens J. H., Felt-Bersma R. J., Schreuder W. O., Eerenberg-Belmer A. J., Paardekooper J., Bronsveld W., Thijs L. G. Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis. Am J Med. 1989 Jan;86(1):20–26. doi: 10.1016/0002-9343(89)90224-6. [DOI] [PubMed] [Google Scholar]
  31. Hakim R. M., Breillatt J., Lazarus J. M., Port F. K. Complement activation and hypersensitivity reactions to dialysis membranes. N Engl J Med. 1984 Oct 4;311(14):878–882. doi: 10.1056/NEJM198410043111403. [DOI] [PubMed] [Google Scholar]
  32. Hartung H. P., Schwenke C., Bitter-Suermann D., Toyka K. V. Guillain-Barré syndrome: activated complement components C3a and C5a in CSF. Neurology. 1987 Jun;37(6):1006–1009. doi: 10.1212/wnl.37.6.1006. [DOI] [PubMed] [Google Scholar]
  33. Hauptmann G., Tappeiner G., Schifferli J. A. Inherited deficiency of the fourth component of human complement. Immunodefic Rev. 1988;1(1):3–22. [PubMed] [Google Scholar]
  34. Hebert L. A., Cosio F. G., Birmingham D. J. The role of the complement system in renal injury. Semin Nephrol. 1992 Sep;12(5):408–427. [PubMed] [Google Scholar]
  35. Hugli T. E., Vallota E. H., Müller-Eberhard H. J. Purification and partial characterization of human and porcine C3a anaphylatoxin. J Biol Chem. 1975 Feb 25;250(4):1472–1478. [PubMed] [Google Scholar]
  36. Hugo F., Krämer S., Bhakdi S. Sensitive ELISA for quantitating the terminal membrane C5b-9 and fluid-phase SC5b-9 complex of human complement. J Immunol Methods. 1987 May 20;99(2):243–251. doi: 10.1016/0022-1759(87)90134-7. [DOI] [PubMed] [Google Scholar]
  37. Ito S., Fujita T., Tamura N. Determination of C4b.C4-bp complex formed by the activation of classical complement pathway using an enzyme-linked immunosorbent assay. J Immunol Methods. 1987 Dec 4;105(1):145–150. doi: 10.1016/0022-1759(87)90425-x. [DOI] [PubMed] [Google Scholar]
  38. Jarvis J. N., Pousak T., Krenz M., Iobidze M., Taylor H. Complement activation and immune complexes in juvenile rheumatoid arthritis. J Rheumatol. 1993 Jan;20(1):114–117. [PubMed] [Google Scholar]
  39. Kazatchkine M. D., Fearon D. T. Deficiencies of human C3 complement receptors type 1 (CR1, CD35) and type 2 (CR2, CD21). Immunodefic Rev. 1990;2(1):17–41. [PubMed] [Google Scholar]
  40. Kerr L. D., Adelsberg B. R., Schulman P., Spiera H. Factor B activation products in patients with systemic lupus erythematosus. A marker of severe disease activity. Arthritis Rheum. 1989 Nov;32(11):1406–1413. doi: 10.1002/anr.1780321109. [DOI] [PubMed] [Google Scholar]
  41. Kirschfink M., Castro F. F., Rother U., Nakhosteen J. A., Deppisch R., Schmitz-Schumann M. Complement activation and C3 allotype distribution in patients with bronchial asthma. Int Arch Allergy Immunol. 1993;100(2):151–155. doi: 10.1159/000236402. [DOI] [PubMed] [Google Scholar]
  42. Kirschfink M., Wienert T., Rother K., Pomer S. Complement activation in renal allograft recipients. Transplant Proc. 1992 Dec;24(6):2556–2557. [PubMed] [Google Scholar]
  43. Kissel J. T., Mendell J. R., Rammohan K. W. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med. 1986 Feb 6;314(6):329–334. doi: 10.1056/NEJM198602063140601. [DOI] [PubMed] [Google Scholar]
  44. Kohsaka T., Abe J., Asahina T., Kobayashi N. Classical pathway complement activation in Kawasaki syndrome. J Allergy Clin Immunol. 1994 Feb;93(2):520–525. doi: 10.1016/0091-6749(94)90362-x. [DOI] [PubMed] [Google Scholar]
  45. Kolb W. P., Morrow P. R., Tamerius J. D. Ba and Bb fragments of factor B activation: fragment production, biological activities, neoepitope expression and quantitation in clinical samples. Complement Inflamm. 1989;6(3):175–204. doi: 10.1159/000463093. [DOI] [PubMed] [Google Scholar]
  46. Lin R. Y., Astiz M. E., Saxon J. C., Saha D. C., Rackow E. C. Alterations in C3, C4, factor B, and related metabolites in septic shock. Clin Immunol Immunopathol. 1993 Nov;69(2):136–142. doi: 10.1006/clin.1993.1161. [DOI] [PubMed] [Google Scholar]
  47. Liszewski M. K., Atkinson J. P. The role of complement in autoimmunity. Immunol Ser. 1991;54:13–37. [PubMed] [Google Scholar]
  48. Maillet F., Frémeaux-Bacchi V., Uhring-Lambert B., Kazatchkine M. D. Assessment of complement activation in clinical samples. Comparison of immunochemical and functional measurements of complement components with quantitation of activation fragments. J Immunol Methods. 1992 Dec 8;156(2):171–178. doi: 10.1016/0022-1759(92)90023-m. [DOI] [PubMed] [Google Scholar]
  49. Malchesky P. S. Artificial surfaces in apheresis devices: interactions with the complement system. J Clin Apher. 1992;7(3):145–146. doi: 10.1002/jca.2920070310. [DOI] [PubMed] [Google Scholar]
  50. Mayes J. T., Schreiber R. D., Cooper N. R. Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum. J Clin Invest. 1984 Jan;73(1):160–170. doi: 10.1172/JCI111187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Mollnes T. E., Lea T., Frøland S. S., Harboe M. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol. 1985 Aug;22(2):197–202. doi: 10.1111/j.1365-3083.1985.tb01871.x. [DOI] [PubMed] [Google Scholar]
  52. Negoro N., Okamura M., Takeda T., Koda S., Amatsu K., Inoue T., Curd J. G., Kanayama Y. The clinical significance of iC3b neoantigen expression in plasma from patients with systemic lupus erythematosus. Arthritis Rheum. 1989 Oct;32(10):1233–1242. doi: 10.1002/anr.1780321008. [DOI] [PubMed] [Google Scholar]
  53. Nilsson U. R., Nilsson B. Simplified assays of hemolytic activity of the classical and alternative complement pathways. J Immunol Methods. 1984 Aug 3;72(1):49–59. doi: 10.1016/0022-1759(84)90432-0. [DOI] [PubMed] [Google Scholar]
  54. Oltvai Z. N., Wong E. C., Atkinson J. P., Tung K. S. C1 inhibitor deficiency: molecular and immunologic basis of hereditary and acquired angioedema. Lab Invest. 1991 Oct;65(4):381–388. [PubMed] [Google Scholar]
  55. Oppermann M., Baumgarten H., Brandt E., Gottsleben W., Kurts C., Götze O. Quantitation of components of the alternative pathway of complement (APC) by enzyme-linked immunosorbent assays. J Immunol Methods. 1990 Oct 19;133(2):181–190. doi: 10.1016/0022-1759(90)90358-3. [DOI] [PubMed] [Google Scholar]
  56. Oppermann M., Höpken U., Götze O. Assessment of complement activation in vivo. Immunopharmacology. 1992 Sep-Oct;24(2):119–134. doi: 10.1016/0162-3109(92)90018-8. [DOI] [PubMed] [Google Scholar]
  57. Oppermann M., Schulze M., Götze O. A sensitive enzyme immunoassay for the quantitation of human C5a/C5a(desArg) anaphylatoxin using a monoclonal antibody with specificity for a neoepitope. Complement Inflamm. 1991;8(1):13–24. doi: 10.1159/000463173. [DOI] [PubMed] [Google Scholar]
  58. Porcel J. M., Peakman M., Senaldi G., Vergani D. Methods for assessing complement activation in the clinical immunology laboratory. J Immunol Methods. 1993 Jan 4;157(1-2):1–9. doi: 10.1016/0022-1759(93)90063-d. [DOI] [PubMed] [Google Scholar]
  59. Rossi Devivo M. L., Romano E. L., Suárez G., Rodríguez M., Blasini A. M., Soyano A. Evaluation of complement activity by an enzyme immunoassay. Int Arch Allergy Immunol. 1993;101(3):234–239. doi: 10.1159/000236451. [DOI] [PubMed] [Google Scholar]
  60. Röther E., Lang B., Coldewey R., Hartung K., Peter H. H. Complement split product C3d as an indicator of disease activity in systemic lupus erythematosus. Clin Rheumatol. 1993 Mar;12(1):31–35. doi: 10.1007/BF02231555. [DOI] [PubMed] [Google Scholar]
  61. Schur P. H., Sandson J. Immunologic factors and clinical activity in systemic lupus erythematosus. N Engl J Med. 1968 Mar 7;278(10):533–538. doi: 10.1056/NEJM196803072781004. [DOI] [PubMed] [Google Scholar]
  62. Scott J. P., Arroyave C. Activation of complement and coagulation in juvenile dermatomyositis. Arthritis Rheum. 1987 May;30(5):572–576. doi: 10.1002/art.1780300513. [DOI] [PubMed] [Google Scholar]
  63. Seifert P. S., Hansson G. K. Complement receptors and regulatory proteins in human atherosclerotic lesions. Arteriosclerosis. 1989 Nov-Dec;9(6):802–811. doi: 10.1161/01.atv.9.6.802. [DOI] [PubMed] [Google Scholar]
  64. Seifert P. S., Messner M., Roth I., Bhakdi S. Analysis of complement C3 activation products in human atherosclerotic lesions. Atherosclerosis. 1991 Nov;91(1-2):155–162. doi: 10.1016/0021-9150(91)90197-b. [DOI] [PubMed] [Google Scholar]
  65. Slotman G. J., Burchard K. W., Williams J. J., D'Arezzo A., Yellin S. A. Interaction of prostaglandins, activated complement, and granulocytes in clinical sepsis and hypotension. Surgery. 1986 Jun;99(6):744–751. [PubMed] [Google Scholar]
  66. Späth P. J., Wüthrich B., Bütler R. Quantification of C1-inhibitor functional activities by immunodiffusion assay in plasma of patients with hereditary angioedema--evidence of a functionally critical level of C1-inhibitor concentration. Complement. 1984;1(3):147–159. doi: 10.1159/000467830. [DOI] [PubMed] [Google Scholar]
  67. Stiehm E. R. Recognition and treatment of immune disorders at the time of birth. Vox Sang. 1986;51 (Suppl 2):30–32. doi: 10.1111/j.1423-0410.1986.tb02004.x. [DOI] [PubMed] [Google Scholar]
  68. Sturfelt G., Sjöholm A. G. Complement components, complement activation, and acute phase response in systemic lupus erythematosus. Int Arch Allergy Appl Immunol. 1984;75(1):75–83. doi: 10.1159/000233593. [DOI] [PubMed] [Google Scholar]
  69. Triolo G., Giardina E., Casiglia D., Scarantino G., Bompiani G. D. Detection of the terminal fluid-phase complement complex, SC5b-9, in the plasma of patients with insulin-dependent (type I) diabetes mellitus. Relation to increased urinary albumin excretion and plasma von Willebrand factor. Clin Exp Immunol. 1991 Apr;84(1):53–58. [PMC free article] [PubMed] [Google Scholar]
  70. Videm V., Fosse E., Mollnes T. E., Garred P., Svennevig J. L. Time for new concepts about measurement of complement activation by cardiopulmonary bypass? Ann Thorac Surg. 1992 Oct;54(4):725–731. doi: 10.1016/0003-4975(92)91018-5. [DOI] [PubMed] [Google Scholar]
  71. Walport M. J., Lachmann P. J. Complement deficiencies and abnormalities of the complement system in systemic lupus erythematosus and related disorders. Curr Opin Rheumatol. 1990 Aug;2(4):661–663. doi: 10.1097/00002281-199002040-00018. [DOI] [PubMed] [Google Scholar]
  72. Walport M. J. The Roche Rheumatology Prize Lecture. Complement deficiency and disease. Br J Rheumatol. 1993 Apr;32(4):269–273. doi: 10.1093/rheumatology/32.4.269. [DOI] [PubMed] [Google Scholar]
  73. Watkins J., Wild G., Smith S. Nafamostat to stabilise plasma samples taken for complement measurements. Lancet. 1989 Apr 22;1(8643):896–897. doi: 10.1016/s0140-6736(89)92883-3. [DOI] [PubMed] [Google Scholar]
  74. West C. D. The complement profile in clinical medicine. Inherited and acquired conditions lowering the serum concentrations of complement component and control proteins. Complement Inflamm. 1989;6(1):49–64. [PubMed] [Google Scholar]
  75. Whaley K., Ahmed A. E. Control of immune complexes by the classical pathway. Behring Inst Mitt. 1989 Jul;(84):111–120. [PubMed] [Google Scholar]
  76. Wild G., Watkins J., Ward A. M., Hughes P., Hume A., Rowell N. R. Complement activation in systemic sclerosis. J Clin Lab Immunol. 1990 Jan;31(1):39–41. [PubMed] [Google Scholar]
  77. Wolbink G. J., Bollen J., Baars J. W., ten Berge R. J., Swaak A. J., Paardekooper J., Hack C. E. Application of a monoclonal antibody against a neoepitope on activated C4 in an ELISA for the quantification of complement activation via the classical pathway. J Immunol Methods. 1993 Jul 6;163(1):67–76. doi: 10.1016/0022-1759(93)90240-8. [DOI] [PubMed] [Google Scholar]
  78. Würzner R., Schulze M., Happe L., Franzke A., Bieber F. A., Oppermann M., Götze O. Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies. Complement Inflamm. 1991;8(5-6):328–340. doi: 10.1159/000463204. [DOI] [PubMed] [Google Scholar]
  79. Zilow G., Naser W., Rutz R., Burger R. Quantitation of the anaphylatoxin C3a in the presence of C3 by a novel sandwich ELISA using monoclonal antibody to a C3a neoepitope. J Immunol Methods. 1989 Jul 26;121(2):261–268. doi: 10.1016/0022-1759(89)90169-5. [DOI] [PubMed] [Google Scholar]
  80. Zilow G., Sturm J. A., Rother U., Kirschfink M. Complement activation and the prognostic value of C3a in patients at risk of adult respiratory distress syndrome. Clin Exp Immunol. 1990 Feb;79(2):151–157. doi: 10.1111/j.1365-2249.1990.tb05171.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Zilow G., Zilow E. P., Burger R., Linderkamp O. Complement activation in newborn infants with early onset infection. Pediatr Res. 1993 Aug;34(2):199–203. doi: 10.1203/00006450-199308000-00020. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Diagnostic Laboratory Immunology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES